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INTRODUCTION
Gene therapy is under investigation as a new method to
treat congenital, neoplastic, and infectious diseases by intro-
duction of therapeutic genes into somatic cells. A number of
hematologic and immunologic disorders may be approached
by gene therapy, using hematopoietic stem cells (HSCs) as the
targets for gene modiﬁcation [1]. To obtain durable expression
of a therapeutic gene in peripheral blood cells of all lineages,
pluripotent human stem cells found within the population of
CD34 cells, which are present in neonatal cord blood, post-
natal bone marrow, or peripheral blood after mobilization
with growth factors, must be the target for the gene transfer.
Retroviral vectors based on the Moloney murine
leukemia virus (MoMuLV) have been demonstrated to suc-
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ABSTRACT
Using retroviral supernatants derived from the amphotropic murine packaging cell line PA317 and the amphotropic
canine packaging cell line (DA), cord blood and mobilized peripheral blood CD34 cells were transduced with the
vector LN (neomycin resistance) and the vector L-TR/TAT neo (neomycin resistance in conjunction with a double-
hammerhead ribozyme conferring anti-HIV activity). Different multiplicities of infection (MOI) were applied in the
setup according to vector titrations on NIH-3T3 cells. PA317-based supernatants were tested at MOI of 10 and 30.
Purified concentrated DA-derived vector preparations were tested at MOI of 10, 30, 100, and 300. Immediately after
transduction, CD34 cells were plated into colony assays in the presence and absence of G418 to evaluate the
amount of gene transfer and potential toxic effects of the vectors on colony growth. The remaining cells were sub-
jected to G418 selection in liquid culture for 12 days and subsequently challenged with HIV-1JR-FL to test for efficacy
of the anti-HIV gene in macrophages derived from transduced CD34 cells. Transduction by the PA317-packaged
vectors was maximal at the lowest MOI used and did not increase with increasing MOI. In contrast, transduction by
the DA-packaged vectors could be progressively increased using increased MOI. The net transduction efficiency per
unit of reverse transcriptase activity in the DA vector preparations was 8.7-fold higher than in the PA317 vector
supernatants. HIV-1 challenge of the cells transduced by the ribozyme vector derived from the PA317 packaging cells
resulted in a 1.5 log inhibition of p24 output compared with the control cells containing neomycin resistance only. A
2.5 log inhibition of p24 output could be observed in the cell population transduced with DA-packaged vector super-
natants. Compared with retroviral supernatants from PA317 packaging cell lines, DA packaging line–derived vector
preparations demonstrated higher transduction efficiency into CD34 cells, particularly at higher MOI, and increased
efficacy of the transferred anti-HIV gene when challenged with HIV-1JR-FL. The increase in transduction efficiency
may be due to a higher ratio of intact vs. defective vector particles in the DA-derived vector preparations.
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cessfully transduce CD34 cells, assayed as colony-forming
units (CFUsor long-term culture initiating cells (LTC-ICs).
One of the key advances leading to the use of retroviral vec-
tors for gene transfer was the development of packaging cell
lines [2]. Packaging cell lines are engineered to express the
genes for the retroviral proteins that make up the retroviral
virion particle—gag, pol, and env [3]. Using packaging cell
lines, the vectors can have all of the viral protein-encoding
genes replaced by the passenger genes. This binary system
allows gene transfer to occur using viral mechanisms, but
prevents subsequent viral replication in transduced target
cells because the genes encoding the viral proteins remain in
the packaging cells. Packaging cell lines based on murine
3T3 ﬁbroblasts (e.g., PA317, AM12, or PsiCrip), which pro-
duce vector particles with an envelope protein derived from
the murine amphotropic virus 4070A [4], have been most
widely used for gene transfer into human cells. When high-
titer clones of vector-producing packaging cells are used to
produce vectors under optimal conditions [5], they typically
produce vectors at titers in the range of 105–107 infectious
units per mL. Using these vector preparations and optimal
transduction conditions (stimulation of the hematopoietic
cells with appropriate combinations of growth factors and
support by stromal cells or ﬁbronectin matrices), transduc-
tion of 25–50% of human CD34 progenitor cells is rou-
tinely achieved [6].
Packaging cell lines based on mouse fibroblasts inher-
ently contain a high burden of endogenous retroviruses.
There have been concerns that activation of these retro-
viruses could generate replication-competent retroviruses
(RCRs) that could cause an active infection in patients
receiving transduced cells [7–9]. Therefore, in recent years,
new packaging cell lines based on cells from other species
have been developed, including canine and human, which
would be expected to have fewer endogenous retroviruses
that could recombine with the vectors to generate RCR
[10–16]. An additional beneﬁt of these cell lines is that they
do not, as far as is known, allow packaging and transmission
of irrelevant contaminating sequences such as VL30 [7,8].
We have compared the gene transfer efficiency into
human CD34 cells between retroviral vectors packaged by
a standard murine ﬁbroblast cell line (PA317) and the same
vectors packaged in a canine fibroblast packaging cell line
(DA). By measuring reverse transcriptase (RT) activity, the
amount of viral particles in DA-packaged vectors was com-
pared with the amount of viral particles in PA317-packaged
vectors and was correlated to the percent of resistant
colonies obtained after transduction of CD34 cells. Fur-
thermore, we have performed challenge experiments on pri-
mary cells derived from CD34 cells that had been trans-
duced with PA317 vector supernatants and DA vector
preparations, both transferring an anti–HIV-1 gene.
MATERIALS AND METHODS
Retroviral vectors
The control retroviral vector used in this study was
LN, containing the neomycin resistance gene driven by the
long terminal repeat (LTR) of the MoMuLV [13,14]. The
vector transferring anti-HIV activity, L-TR/TAT-neo, con-
tained sequences encoding two hammerhead ribozymes,
cleaving in the tat and rev regions of the HIV-1 RNA,
cloned into the Bcl I site immediately 5 of the neo gene in
the LN vector [14].
The LN and L-TR/TAT-neo vectors were packaged
from their plasmids in PA317 and DA amphotropic packaging
cells. The PA317 cell line [15] was provided by A.D. Miller
(Fred Hutchinson Cancer Center, Seattle, WA) and was
maintained in D10 (Dulbecco’s modified Eagle’s medium,
high glucose [DMEM; Irvine Scientiﬁc, Santa Ana, CA], 10%
fetal bovine serum {FBS}, 2 mmol/L L-glutamine, 50 U/mL
penicillin, 50 g/mL streptomycin). The DA packaging cell
line has been described previously [9,19,20]. Brieﬂy, the dog
osteosarcoma line D17 (ATCC #CCL 183) was cotransfected
with a Moloney gag-pol [16] expression plasmid driven by the
cytomegalovirus (CMV) immediate early (IE) promoter [17]
and a dihydrofolate reductase expression plasmid [18]. After
selection with methotrexate and dipyridamole, clones were
isolated and analyzed for level of expression by Western blot
and a functional transduction assay. The most active clone,
DA/gag-pol, was then cotransfected with a CMV IE-driven
expression plasmid encoding the amphotropic 4070A enve-
lope [19] and the phleomycin resistance plasmid pUT507
[20]. After selection with phleomycin, clones were isolated
and tested for level of envelope expression and functional
titer-generating activity with typical neomycin resistance and
-galactosidase–encoding vectors. The best clones typically
yielded about four- to ninefold higher titers in vector produc-
ing pools for a specific vector compared with that seen in
PA317. Clones were also tested for lack of generation of
RCRs [21]. From this process, the clone DA was chosen as a
packaging cell line. This clone was banked and aliquots from
the bank used to generate vector-producing cell lines. All
manipulations were carried out in D10 medium (DMEM,
high glucose [Irvine Scientiﬁc], 10% FBS [Hyclone, Logan,
UT], and 2 mM/L L-glutamine).
Clones of PA317 producer cell lines were established as
described previously [14]. High-titer vector-containing
supernatant was collected after conditioning of D10 for 24
hours by confluent monolayers of vector-producing cells
maintained at 32C in 5% CO2. Aliquots of vector super-
natants were frozen and stored at –70C.
Vector producer lines were generated from DA as follows:
plasmids encoding the vectors LN and L-TR/TAT-neo were
separately transiently cotransfected with a VSV G envelope
protein encoding plasmid to yield VSV G pseudotyped vector
particle preparations [22]. These preparations were then trans-
duced into fresh DA cells at an MOI of about 1, transductants
selected in neomycin, and clones isolated by two rounds of
limiting dilution. These clones were then screened for titer,
absence of RCRs and mycoplasma, and sterility. The selected
clones, DA-LN and DA-L-TR/TAT-neo, were banked and
tested according to the relevant Food and Drug Administra-
tion Points to Consider [23–25].
DA producer cells and vector production/concentration
Unprocessed vector supernatants were collected from
conﬂuent monolayers of vector-producing cell line clones,
filtered through a 0.45m filter, and frozen in aliquots at
–80C. Concentrated retroviral vectors were produced using
the canine-derived DA packaging cell line. The cells were
cultured at 37C using a Cell Cube (Corning-Costar, Cam-
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bridge, MA) culture system. Cells were allowed to expand,
and supernatants were harvested over a period of 8–10 days.
Harvested supernatants were clarified using standard car-
tridge ﬁltration, concentrated using standard tangential ﬂow
ultraﬁltration, treated with DNase1, diaﬁltered, and passed
over a size-exclusion chromatography column. Vector was
collected from the void volume and further concentrated
using tangential ﬂow ultraﬁltration. The vector material was
then formulated in a tris/lactose formulation buffer contain-
ing NaCl and human serum albumin. The final vector
preparations were stored frozen in aliquots at –80C.
Titration of vector supernatants
After thawing, both PA317 and DA-based vector super-
natants were ﬁltered (0.45m), and the amounts of virus pres-
ent were determined using a sensitive RT assay as reported
previously [26] and by measuring infectious titer by endpoint
dilution of biological activity (transfer of G418-resistance).
Brieﬂy, titers were measured by making 10-fold serial dilu-
tions of both PA317-based and DA-based vector supernatants
using D10 medium. 3T3 cells in log phase of growth were
exposed to 1 mL of each vector dilution at 37C and 5% CO2
overnight. The next day, vector dilutions were replaced with
D10 containing G418 (0.5 mg/mL, Geneticin, Gibco/Life
Technologies, Grand Island, NY) and incubated with the cells
for 10 days. After the incubation period, dead cells were
washed off, the remaining adherent G418-resistant colonies
were stained with methylene blue (Sigma, St. Louis, MO),
and colonies were counted. The titer was determined as the
number of colonies counted in the last dilution giving rise to
G418-resistant colonies multiplied by the dilution factor.
Human hematopoietic cells
Human CD34 hematopoietic progenitor cells from
uninfected individuals were obtained from umbilical cord
blood samples (provided by the obstetrical nurses at Kaiser-
Permanente Hospital, Los Angeles, CA, with permission
from the Committee on Clinical Investigations of Childrens
Hospital Los Angeles, CA). Mononuclear cells were isolated
by Ficoll-hypaque separation (Sigma), followed by CD34
cell enrichment using the Mini-Macs system (Miltenyi,
Auburn, CA). Peripheral blood stem cells (PBSC) from an
HIV-1 seropositive volunteer were obtained by granulocyte
colony-stimulating factor (G-CSF) mobilization and aphere-
sis, followed by CD34 cell separation in a CEPRATE SC
Stem Cell Concentrator (CellPro, Seattle, WA) [27]. CD34
cells were grown in I20 (Iscove’s modiﬁed Dulbecco’s medi-
um [IMDM, Irvine Scientiﬁc]; 20% FBS [Bio Whittacker,
Walkersville, MD], 1% deionized bovine serum albumin
[Sigma], 2 mmol/L L-glutamine [Irvine Scientiﬁc], 50 U/mL
penicillin [Irvine Scientiﬁc], 50 g/mL streptomycin [Irvine
Scientific], 10–6 mol/L hydrocortisone [Sigma], and 10–4
mol/L mercaptoethanol [Sigma]).
Establishment of stromal cell layers
Normal human bone marrow stromal cell cultures were
established as reported previously [28]. The murine bone
marrow stromal cell line S17 was provided by Kenneth Dor-
shkind (University of California, Los Angeles, CA), and
maintained in D10 [29]. G418-resistant S17 cells (LN-S17),
for support of hematopoietic cells during G418 selection,
were produced, as previously reported, by transduction with
the LN vector and selection in 1.0 mg/mL G418 [30].
Evaluation of clonogenic ability and gene transfer into
CD34 cells
CD34 cells were transduced on heterologous bone
marrow stroma layers, as reported previously [26]. Immedi-
ately after transduction, samples of the CD34 cells were
plated in methylcellulose-based colony assays in the pres-
ence and absence of G418 to evaluate the clonogenic ability
and percentage of G418-resistant progenitor cells [28].
Colony counts and percentages of G418-resistant colonies
were determined as described previously [26].
G418 selection of transduced CD34 cells
Selection for hematopoietic cells that had been trans-
duced and, therefore, contained the neomycin resistance
gene, was performed over a period of 12 days in G418 (0.75
mg/mL active compound) on a neomycin-resistant S17 stro-
ma layer [26]. During this time, the CD34 cells differenti-
ated into cultures consisting mainly of monocytic cells,
which can be productively infected with HIV-1 [30].
HIV-1 infection of monocytic cells derived from transduced
CD34 cells
As described previously, monocytic cells derived from
transduced G418-selected long-term bone marrow cultures
(LTBMCs) were infected with HIV-1 by exposing 1106
cells to HIV-1JR-FL stock at an MOI of 0.01 [26]. After infec-
tion, supernatant samples were taken weekly from the cul-
tures for measurements of HIV-1 core protein (p24) in the
Coulter p24 assay (Immunotech, Westbrook, MA).
RESULTS
Development of retroviral vectors
The retroviral vectors LN (neomycin resistance) and L-
TR/TAT-neo (two hammerhead ribozymes against HIV-1
and neomycin resistance) were established as reported previ-
ously. Each vector was packaged using the amphotropic
packaging cell line PA317 and the amphotropic canine pack-
aging cell line DA. Previous studies have shown that the L-
TR/TAT-neo vector, produced from PA317 cells, effectively
suppresses HIV-1 replication in transduced CEM T lym-
phocytes and CD34 cells from HIV-1– and HIV-1 indi-
viduals [14,26]. The vectors produced by PA317 cells were
used as unprocessed culture medium conditioned by the
packaging cells. The vectors produced by the DA cells were
either used as unprocessed culture medium or processed to
remove culture medium components and to concentrate the
vector to high titer.
The titers that were measured as infectious units/mL
from the vector preparations were: PA317-LN, 6106;
PA317-L-TR/TAT-neo, 1106; DA-LN (unprocessed),
1107; DA-L-TR/TAT-neo (unprocessed), 1107; DA-LN
(concentrated), 2.3109; and DA-TR/TAT-neo (concentrat-
ed), 3109.
Clonogenic ability of transduced CD34 cells
To assess potential toxicities from the different retroviral
vector preparations, human CD34 cells were transduced
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with the PA317 and DA-based supernatants at a range of
MOI and then plated in colony assays to measure the num-
bers of viable hematopoietic progenitor cells capable of giv-
ing rise to colonies of mature blood cells. In three experi-
ments, CD34 cells transduced with vectors that were
derived from the PA317 packaging cell line (LN, L-
TR/TAT-neo) at MOI of 10 and 30 gave rise to similar num-
bers of colonies as those produced from CD34 cells after
mock transduction (no vector) (Table 1). CD34 cells trans-
duced with vectors derived from the DA packaging cell line
at MOI of 10, 30, 100, and 300 also gave rise to similar num-
bers of colonies compared with mock transduced CD34
cells (Table 1). Thus, none of the vector preparations showed
toxicity to clonogenic progenitor cells at the MOI used.
To assess potential toxicity to long-lived progenitor cells
by the retroviral vectors, samples of the transduced CD34
cells were used to initiate LTC-ICs, which were evaluated
after 5 weeks by plating samples in the assay for the colony-
forming cells. Again, similar numbers of colonies were
observed in both the vector-transduced cultures at all MOI
and the mock-transduced controls (Table 1).
Evaluation of transduction efficiency
Because all vectors used for the transductions contained
the neomycin resistance gene, gene transfer efﬁciency could
be estimated by determining the number of G418-resistant
CFUs.
Experiments were performed to compare PA317-
derived vector supernatants with DA-derived unprocessed
vector preparations (not concentrated). The MOI used was
10. In two experiments, the extent of G418 resistance in the
PA317 group averaged 12%, while the unprocessed DA vec-
tor group reached an average of 21% G418 resistance, an
approximate twofold increase over the PA317 vector arm
(Fig. 1A and B). Statistical analysis (analysis of variance
[ANOVA]) of data pooled from both experiments resulted in
a p value of 0.015239, demonstrating a statistically signiﬁ-
cant increase in G418 resistance after transduction of
CD34 cells with DA-derived unprocessed vector prepara-
tions compared with PA317-derived vector supernatants.
In two experiments, transductions by PA317-derived
vector supernatants were compared with transductions by
concentrated DA vector preparations (Table 1). Using the
PA317 supernatants, the extent of gene transfer by the LN-
and L-TR/TAT-neo vectors into clonogenic progenitor
cells averaged 29.3% (2.557 standard error of the mean
[SEM]) at an MOI of 10, and 29.7% (2.601 SEM) at an
MOI of 30. Using the DA-derived vectors, the extent of
gene transfer by the LN- and L-TR/TAT-neo vectors aver-
aged 38.5% (1.902 SEM) at an MOI of 10 and 48.8%
(9.198 SEM) at an MOI of 30. After statistical analysis
(ANOVA), the differences in G418 resistance after trans-
duction with PA317 supernatants and DA-derived concen-
trated vector preparations at an MOI of 10 and 30 were
shown to be signiﬁcant (p 	 0.028109).
Because the DA-based vectors were concentrated to titers
above 108 CFUs/mL, higher effective MOI could be achieved
by simply performing less dilution of the concentrated vector
preparations. At an MOI of 100, an average of 60% (9.198
SEM) of G418-resistant CFUs were obtained; at an MOI of
300, 61.5% (10.35 SEM) of G418-resistant CFUs could be
observed (Fig. 2A). Thus, the percentages of G418-resistant
progenitors were the same with the PA317-packaged vectors
at MOI of either 10 or 30 ( p value of the differences in G418
resistance at an MOI of 10 and 30 	 0.911050). In contrast,
the percentages of G418-resistant progenitors following
transduction with the DA vectors increased progressively as
the MOI increased from 10 to 30, and continued to increase
at the higher MOI of 100. The statistical analysis of the
increase in transduction frequency (general mixed model
Table 1. Number of colonies after transduction of CD34 cells with DA- and PA317-derived vector at increasing MOI
Number of colonies formed with/without G418 (% G418 resistance)
Experiment No vector MOI 10 MOI 30 MOI 100 MOI 300
Number 1a
Mock 23/873 (2.6)
DA-LN 369/884 (39.1) 385/853 (42.4) 420/867 (45.8) 407/857 (44.8)
LN 246/867 (25.7) 249/848 (26.7)
DA-TR/TAT 322/862 (34.7) 340/872 (36.4) 411/876 (44.3) 321/704 (42.3)
L-TR/TAT 241/890 (24.5) 244/822 (24.4)
Number 2a
Mock 44/503 (8.7)
DA-LN 216/470 (36.6) 264/488 (45.1) 372/488 (67.2) 405/450 (80.0)
LN 204/506 (31.6) 207/512 (31.8)
DA-TR/TAT 254/483 (43.5) 363/447 (71.4) 413/446 (82.7) 414/470 (78.7)
L-TR/TAT 219/494 (35.4) 218/484 (36.0)
Number 2 (5w LTBMC)b
Mock 0/160 (0)
DA-LN 30/168 (17.9) 35/163 (21.5) 59/153 (38.6) 75/177 (42.4)
LN 20/155 (12.9) 22/154 (14.3)
DA-TR/TAT 35/149 (23.5) 41/155 (26.5) 74/162 (45.7) 72/158 (45.5)
L-TR/TAT 20/168 (11.9) 20/164 (12.2)
aColonies plated immediately after completion of transduction.
b5w LTBMC, colonies plated after the growth of transduced CD34 cells in long-term bone marrow culture for 5 weeks.
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ANOVA) showed a signiﬁcant increase in G418 resistance to
the MOI of 100 (p 	 0.025041). No signiﬁcant increase of
transduction occurred with increasing the MOI from 100 to
300 ( p 	 0.920014). In all groups, the outcome of DA-LN
and DA-TR/TAT transductions were not signiﬁcantly differ-
ent (ANOVA, p 	 0.337962). The outcome of LN and L-
TR/TAT transductions were also not signiﬁcantly different
from each other (p 	 0.843869).
To evaluate the percentages of transduced progenitor
cells among the more primitive LTC-IC population, trans-
duced CD34 cells were grown in LTBMC for 5 weeks.
Then cells were harvested and plated in colony assays to
evaluate the ability of progenitor cells to form colonies in
the presence and absence of G418 (Table 1). The extent of
G418-resistant LTC-ICs using PA317-based vectors aver-
aged 12.4% (0.5 SEM) at an MOI of 10, and 13.3%
(1.05 SEM) at an MOI of 30. Using DA-derived vectors,
the amount of G418-resistant LTC-ICs was 20.7% (2.8
SEM) at an MOI of 10, 24.0% (2.5 SEM) at an MOI of
30, 42.2% (3.55 SEM) at an MOI of 100, and 43.4%
(1.55 SEM) at an MOI of 300 (Fig. 2B). Thus, the relative
percentages of transduced progenitors that were produced
by each vector preparation measured directly after transduc-
tion remained stable after 5 weeks of long-term culture,
with the DA-packaged vectors achieving higher gene trans-
fer than the PA317-packaged vectors.
Comparison of RT activity and transduction efficiency
To estimate the amount of retroviral vector particles
present in the supernatants used for transduction of CD34
cells, a sensitive RT assay was performed and compared with
the infectious titer. In four experiments, at equivalent dilu-
tions of vector supernatants (MOI of 30), the PA317-pack-
aged samples had an average of 3155 (360 SEM) counts
per minute (CPM) of RT activity, while DA-packaged
supernatants averaged 758 (175 SEM) CPM of RT activi-
ty. And yet, despite the lower concentration of viral particles
as measured by RT activity in the DA vector preparations
Figure 1. Comparison of gene transduction of hematopoietic progenitor cells by PA317- and DA-packaged vector supernatants 
All supernatants were added at an MOI of 10 infectious units (based on transduction of 3T3 cells) per CD34 cells. CD34 cells were plated in colony assay after
the third day of transduction, and the percentages of G418-resistant colonies present after 14 days were determined. (A) Cells were transduced by PA317-packaged
LN vector, PA317-packaged L-TR/TAT vector, or DA-packaged L-TR/TAT vector. (B) Cells were transduced by PA317-packaged LN vector, PA317-packaged
L-TR/TAT vector, DA-packaged LN vector, or DA-packaged L-TR/TAT vector.
Figure 2. Comparison of gene transduction of hematopoietic progenitor cells by PA317- and DA-packaged vectors at various MOI
Supernatants were added to CD34 cells at the indicated MOI. (A) CD34 cells were plated in colony assay after the third day of transduction and the percentages of
G418-resistant colonies present after 14 days were determined. Data shown are the averages of four experiments. (B) Portions of the transduced CD34 cells were
maintained in long-term bone marrow culture for 5 weeks and then plated in colony assay to determine the percentages of G418-resistant long-term culture initiating
cell progenitors. Data shown are the averages of two experiments.
A B
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compared with the PA317 supernatants, the transduction of
CD34 cells by these supernatant dilutions (MOI 	 30)
yielded an average of 50% (9 SEM) G418-resistant CFUs
with the DA vector preparations and only 32.7% (5.3
SEM) with the PA317 supernatants. Figure 3 shows these
data expressed as net transduction (% G418-resistant CFUs)
per units of viral particles (500 U of RT activity). The net
transduction efficiency per units of viral particles by the
DA-packaged vectors (39.2%) was 8.7-fold higher than for
the PA317-packaged vectors (5.3%). Statistical analysis of
these four experiments demonstrates the differences in net
transduction efﬁciency per RT units to be signiﬁcant (Stu-
dent’s t-test, p 	 0.022385).
Competition of DA-packaged vector by PA317-packaged
vectors
The failure of transduction of CD34 cells to increase as
the MOI of PA317-packaged vector increased and the ﬁnding
of higher net transduction efﬁciency per units of viral particles
by the DA-packaged vector compared with the PA317-pack-
aged vector suggested that the PA317 vector preparations con-
tained noninfectious virions, which may block receptors and
prevent increased transduction as more vector is added. To test
this possibility, we performed a mixing experiment in which
increasing amounts of PA317-packaged vector were added to a
constant amount of DA-packaged vector (Fig. 4). As before,
the extent of transduction by the DA-packaged LN vector
(46.6%) exceeded that by the PA317-packaged LN vector
(21.2%) when used at an MOI of 30. When increasing
amounts of the PA317-packaged LN vector supernatant were
added to a constant amount of DA-packaged LN vector (MOI
	 30), a signiﬁcant reduction in the percentage of G418-resis-
tant colonies was observed with higher amounts of PA317-
packaged supernatant added (MOI of 10 and 30). With the
highest amount of PA317-packaged vector supernatant added
(MOI 	 30), the percentage of G418-resistant colonies
(26.7%) was reduced to almost the same percentage seen with
the PA317-packaged vector alone (21.2%) (Fig. 4), suggesting
that the PA317-packaged supernatant was able to competitive-
ly inhibit transduction by the DA-packaged vector.
Evaluation of protection of gene-containing
myelomonocytic cells from HIV-1 challenge
An in vitro model for evaluating the inhibition of HIV-1
replication in human myelomonocytic cells derived from
CD34 cells was used as reported previously [26,30]. The
vectors LN (transferring neomycin resistance) and L-
TR/TAT (double-hammerhead ribozyme transferring
anti–HIV-1 activity), packaged by both the PA317 and the
DA amphotropic packaging cell lines, were used to trans-
duce G-CSF–mobilized peripheral blood CD34 cells at an
MOI of 2 for three cycles. After transduction, G418 selec-
tion of the CD34 cells was performed for 12 days on a
monolayer of the murine stromal cell line S17 [29], which
supports human hematopoietic cell survival and differentia-
tion, and had been made resistant to the toxic effects of
G418 by transduction with the LN vector (LN-S17) [30].
After the selection period, the cells were allowed to recover
for 4 days and then challenged with the macrophage-tropic
isolate HIV-1JR-FL. After overnight exposure to HIV-1 fol-
lowed by washing to remove remaining HIV-1 virions, the
cells were grown in LTBMC on a layer of S17 stromal cells
and monitored weekly for p24 output for 42 days.
In two challenge experiments with HIV-1JR-FL, the con-
trol cultures, containing mature myelomonocytic cells pro-
duced from the PA317-LN and DA-LN transduced CD34
cells, were capable of supporting vigorous growth of HIV-
1JR-FL (Fig. 5). HIV-1 core protein (p24) output reached lev-
els into the nanogram per milliliter range. Both vectors
transferring neomycin resistance only (PA317-LN and DA-
LN) allowed for similar growth of HIV; the differences in
p24 output in these groups were not statistically signiﬁcant
(Student’s t-test, p 	 0.234512). In the LTBMC established
from CD34 cells transduced with the PA317-packaged L-
TR/TAT-neo vector, a 1.5 log reduction of p24 output was
achieved compared with the amount of HIV-1 produced by
the control cultures transduced by the LN vector
(92.4–98.4% inhibition). In the cultures established from
CD34 cells transduced with the DA-packaged L-TR/TAT-
Figure 3. Transduction efficiency of CD34 cells (% G418-resistant
colonies) based on reverse transcriptase activity (500 CPM of RT)
of vector supernatants
LN vector supernatants packaged by either the DA or the PA317 packaging
cell line were used to transduce CD34 cells at an MOI of 30. The percent
transduction (% G418-resistant CFUs) and the RT activities were measured.
Figure 4. Transduction of CD34 cells by mixtures of DA- and
PA317-packaged LN vector supernatants
Supernatants were added to CD34 cells at the indicated MOI. CD34 cells
were plated in colony assay after the third day of transduction and the percent-
ages of G418-resistant colonies present after 14 days were determined.
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neo vector, a 2.5 log reduction of p24 output was
achieved compared with the amount of HIV-1 pro-
duced by the control cultures (99.5–99.7% inhibition).
Statistical analysis showed that the differences in inhibition
of HIV-replication by the DA-packaged TR/TAT-neo vec-
tor compared with the same vector packaged in PA317 cells
were signiﬁcant (Student’s t-test, p 	 0.011880).
DISCUSSION
In this study, we have compared amphotropic retroviral
vector supernatants produced in two different packaging
cell lines, the murine 3T3 ﬁbroblast-based PA317 line and
the canine osteosarcoma-based DA line. Importantly, the
same retroviral vector constructs were used from both lines
to allow comparisons of the properties of the two different
packaging cell lines. These vectors are standard MoMuLV-
based retroviral vectors carrying either the bacterial
neomycin resistance gene alone (LN) or a gene inserted
into LN sequences that encodes two distinct hammerhead
ribozymes, which speciﬁcally cleave the HIV-1 RNA tran-
scripts. Both the PA317 and DA packaging cell lines use the
same MoMuLV proteins to form the virion capsid (gag) and
enzymatic functions (pol), and contain the amphotropic
envelope glycoprotein derived from the 4070A amphotrop-
ic isolate [4]. Thus, any differences in properties of the vec-
tors produced reflect influences of the packaging cells
themselves. These may be due to differences in cellular
components incorporated into the virion, e.g., the cellular
membrane lipids and cellular membrane proteins that, with
the virally-encoded envelope glycoprotein, comprise the
virion envelope. For example, species-specific patterns of
glycosylation, which differ between human and murine cel-
lular glycoproteins, affect the sensitivity to complement-
mediated neutralization of viruses produced by this cell
type [33]. Alternatively, the lipid composition of the cell
membrane or aspects of the cytoskeletal organization of the
cell may subtly inﬂuence the ability of viral components to
assemble, bud off for virion release, or mature after release.
Substances released from the packaging cells, such as extra-
cellular matrix molecules [33] or cytokines [34], may also
have effects on target cells.
Because of concerns about production of RCR from
murine-based packaging cells, lines have been derived from
canine [9] or human ﬁbrosarcomas [11] or from the human
embryonic kidney cell line 293 [10,12]. An unanticipated
beneﬁt of these non-murine cell-based packaging lines has
been a higher transduction efﬁciency of the vector prepara-
tions. Besides our ﬁndings reported here, two other studies
have described higher extents of transduction of primary
human cells (melanoma cells and CD34 hematopoietic
progenitor cells) by vectors produced in 293 cells compared
with equivalent titers of vectors from murine cell-based
packaging cell lines [35,36]. The discrepancy between infec-
tivity of cells transduced in bulk compared with the meas-
ured titers of vectors by endpoint dilution assays has previ-
ously been reported [37]. The explanation put forth is that
vector preparations may have a large fraction of interfering
particles, i.e., noninfectious virions, virions carrying unde-
sired messages like VL30 [8], or free envelope glycoprotein,
which can interfere with transduction by the infectious viri-
on by competition for cell surface receptors. At endpoint
dilution, the method traditionally used to measure viral titer
and thus calculate MOI, the interfering particles become
sufficiently diluted so that they do not effectively block
binding of infectious viruses. However, in non-diluted vec-
tor supernatants used for transduction of cells in bulk, the
relative ratios of infectious to interfering particles can affect
the extent of transduction.
Our ﬁnding of higher extents of transduction of human
CD34 hematopoietic progenitors cells by the DA-packaged
vectors than by equivalent MOI of PA317-packaged vectors
are consistent with this explanation. We found that the ratio
of infectious units (measured by bulk transduction of CD34
cells) to the total amount of virus particles (measured by RT
assay) was at least eightfold higher for the DA-based vectors
than for the PA317-based vectors. These data imply that DA
cells produce a higher percentage of infectious virions than
do the PA317 cells, possibly due to more efficient virion
assembly or release. The higher amounts of interfering parti-
cles in the PA317-packaged vector preparations prevent
increased transduction as the MOI is increased.
In contrast, the DA-based vector preparations, because
they are freer of interfering particles, may cause increased
transduction as more viruses are added to target cells. The
ability of the PA317-based vector preparations to inhibit
transduction by the DA-based vector in the mixing experi-
ment is also consistent with the presence of noninfectious
virions in the PA317-based vectors that bind to the
amphotropic virus receptor and compete with the infectious
DA-based vectors. However, it is not possible to rule out
other nonspeciﬁc inhibitory mechanisms.
Some DA vector preparations used were concentrated to
extremely high titers (
108 CFUs/mL) using a counterﬂow
Figure 5. Comparison of inhibition of HIV-1 replication by DA- and PA317-packaged L-TR/TAT vectors in transduced G418-selected
CD34cells in long-term bone marrow culture
CD34 cells were transduced by the indicated vector, selected in G418, and challenged by the addition of HIV-1 of the JR-FL strain. Samples of the culture media
were collected and evaluated for HIV-1 replication by measurement of p24 by ELISA assay. (A) and (B) represent two separate experiments.
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procedure. Concentrated vector appears as a translucent liq-
uid and can be stored at –70C for long intervals. The con-
centration process has multiple benefits, including the
removal of most of the cell culture medium components used
to grow the producer cells and a signiﬁcant reduction in the
volume of the vector that simpliﬁes storage and shipment.
Additionally, vectors concentrated to high titer can deliver
more virus particles in procedures that involve direct in vivo
administration for which only small volumes can be injected.
Due to the high titer of the concentrated DA-based vector,
multiplicities of infection much higher than previously possi-
ble could be achieved and evaluated in transduction experi-
ments using CD34 cells. We found that for the DA prepara-
tions (but not for the PA317 preparations) there were pro-
gressively higher extents of transduction with higher MOI of
vector, which seemed to plateau at an MOI of 100. Impor-
tantly, there was no detectable toxicity to clonogenic pro-
genitor cells after 3 days of transduction using DA-based vec-
tors at MOI between 10–300.
One benefit from the higher transduction of CD34
progenitor cells, achieved using the DA-packaged
anti–HIV-1 ribozyme vector, was increased resistance to
HIV-1 replication compared with cells transduced with the
same anti–HIV-1 ribozyme vector packaged by PA317 cells.
Because the cells transduced by both vector preparations
were selected in G418 before growth in LTBMC and HIV-1
challenge, the better resistance produced by the DA-pack-
aged vector cannot simply be the result of transduction of a
higher percentage of cells. Potentially, the more effective
transduction by the DA-packaged vector may result in some
cells receiving more than one copy of vector, allowing
expression of more anti–HIV-1 ribozyme.
The ultimate importance of improved transduction by
the DA-packaged vector would be higher transduction of
pluripotent human stem cells in the transplant setting. Poor
human stem cell transduction continues to be the rate-limit-
ing step in the effective use of clinical gene therapy for
hematopoietic and lymphoid disorders [38]. While the DA-
packaged vectors clearly could transduce higher percentages
of clonogenic progenitors and even LTC-ICs, these surro-
gate assays have not predicted successful transduction of
pluripotent long-term–engrafting hematopoietic stem cells
[1,6]. Direct comparisons of the different vector prepara-
tions in either large animal gene transfer/bone marrow
transplantation models or clinical trials will be needed to
critically evaluate whether the use of the DA-packaged vec-
tors that we report here will translate into increased extents
of HSC transduction. A clinical trial using the DA-packaged
L-TR/TAT and LN vectors in G-CSF–mobilized CD34
PBSC of HIV-1–infected adults has recently been complet-
ed [39]. Findings from this study will provide the ﬁrst infor-
mation on the efficacy of the DA-packaged vectors for
transduction of pluripotent HSCs in human subjects.
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